--- title: "Who Qualifies for GLP-1 in India" description: "GLP-1 eligibility in India: BMI thresholds, ICMR/RSSDI guidelines, comorbidities, and thin-fat phenotype considerations." canonical: "https://www.kesho.health/keywords/who-qualifies-glp-1" markdown_url: "https://www.kesho.health/md/keywords/who-qualifies-glp-1" language: "en-IN" primary_keyword: "who qualifies GLP-1 India" --- # Who qualifies for GLP-1 therapy in India? > **Short answer:** In India, GLP-1 therapy may be considered for type 2 diabetes when first-line treatment fails, and for obesity at BMI ≥27.5 without comorbidities or ≥25 with comorbidities (prediabetes, hypertension, NAFLD). Final eligibility is determined by your physician after full assessment. **Canonical HTML:** https://www.kesho.health/keywords/who-qualifies-glp-1 **Markdown:** https://www.kesho.health/md/keywords/who-qualifies-glp-1 ## Before your appointment **Free lab prep scan** — Upload your lab report and get a personalised checklist for your endocrine visit — HbA1c, lipids, kidney function, and questions to ask. [Free lab prep scan](https://www.kesho.health/lab-prep-scan) **GLP-1 readiness check** — Educational self-assessment on eligibility signals, safety flags, and what to discuss with your doctor — not a prescription. [GLP-1 readiness check](https://www.kesho.health/glp-1-assessment) ## BMI thresholds for Indian patients ICMR and RSSDI use lower BMI cut-offs than Western guidelines because South Asians develop metabolic complications at lower body weights. Waist circumference above 90 cm (men) or 80 cm (women) adds risk even at "normal" BMI. ## Diabetes vs obesity indications For type 2 diabetes, inadequate HbA1c control despite metformin and lifestyle is the primary trigger. For obesity-only prescribing, structured lifestyle intervention must typically precede pharmacotherapy. ## Who should not take GLP-1 Contraindications include pregnancy, MTC/MEN2 history, severe pancreatitis, and type 1 diabetes. Caution in gastroparesis, active eating disorders, and frail elderly patients. ## Thin-fat phenotype and waist circumference South Asian patients may qualify at BMI 25–27 with central adiposity when waist exceeds 90 cm (men) or 80 cm (women) alongside prediabetes, hypertension, or NAFLD. Visual slimness does not exclude metabolic risk—bring waist measurements and recent labs to consultations. ## Prediabetes and PCOS pathways Prediabetes with elevated BMI often triggers endocrine evaluation for GLP-1 when lifestyle programmes fail to normalise glucose. PCOS patients with insulin resistance may be discussed in joint gynaecology–endocrinology clinics—GLP-1 RAs are not fertility drugs and require contraception during use. ## Documentation your doctor expects Prepare twelve-month weight trend, prior diet and exercise attempts, current medicines including ayurvedic supplements, HbA1c and fasting glucose results, blood pressure readings, and family diabetes history. Structured documentation shortens corridor consultations and supports ICMR-aligned shared decisions. ## Specialists who assess eligibility Endocrinologists, internal medicine specialists, and cardiologists frequently evaluate GLP-1 candidacy in Indian metros and tier-2 referral centres. Primary physicians may initiate or refer based on local expertise. Eligibility is never determined by online quizzes or pharmacy staff—only your treating physician after full assessment. ## Bariatric surgery versus GLP-1 threshold ICMR may recommend bariatric surgery at BMI ≥37.5 or ≥32.5 with severe comorbidities after documented medical weight-loss attempts. GLP-1 pharmacotherapy often precedes or follows surgery in stepped obesity care—discuss sequencing with bariatric and endocrine teams rather than treating them as competing options. ## Employer health checks and screening Corporate annual health camps increasingly flag prediabetes and elevated waist circumference—bring camp reports to specialist consultations. Screening alone does not qualify you for GLP-1; documented lifestyle attempts and physician assessment remain required. Use screening as a conversation starter, not a self-diagnosis. ## Full eligibility guide on Kesho Our who-qualifies cornerstone explains ICMR BMI thresholds, thin-fat phenotype, diabetes versus obesity pathways, and contraindications in 3,700+ words. This landing summarises search queries; the complete guide includes tables, FAQs, and references for appointment preparation. ## Children and adolescents Paediatric GLP-1 use is highly restricted and specialist-led—do not apply adult social-media narratives to teenagers. Family obesity programmes emphasise lifestyle first. Paediatric endocrinology referral is mandatory when adolescent BMI and comorbidities meet exceptional criteria. ## Prediabetes without obesity Prediabetes alone rarely triggers GLP-1 prescribing without elevated BMI or additional comorbidities per ICMR framing. Lifestyle intervention remains first-line. Bring oral glucose tolerance or HbA1c trends to consultations—single borderline readings need confirmation before pharmacotherapy discussions. ## Documentation for insurance appeals If employer insurance requires obesity comorbidity proof, gather lab reports, physician letters, and structured lifestyle attempt logs. Appeals rarely succeed for weight-only indications but diabetes-labelled use with prior authorisation occasionally clears in corporate plans—verify policy wording in writing. ## Shift workers and metabolic risk Indian IT and healthcare shift workers often show worsened glucose tolerance and central adiposity—bring occupational history to consultations. Irregular sleep does not automatically qualify for GLP-1 but contextualises BMI and waist trends alongside lab results. ## Family history and genetic risk Strong family history of type 2 diabetes supports metabolic risk assessment at lower BMI thresholds. Genetics do not replace BMI and comorbidity criteria—physicians integrate family history with waist circumference, HbA1c, and liver enzymes for eligibility decisions. ## Language and health literacy Request explanations in a language you fully understand—many metro specialists offer counselling in regional languages. Bring a family member to appointments if medical terminology feels overwhelming. Kesho publishes GLP-1 drug-class education in 13 Indian languages (English plus Hindi, Bengali, Tamil, Telugu, Marathi, Gujarati, Kannada, Malayalam, Punjabi, Odia, Urdu, and Assamese), reviewed by endocrinologists, internal medicine specialists, and cardiologists; your clinician personalises guidance to your profile. ## Assessment tool on Kesho Our readiness assessment organises questions about BMI, comorbidities, and goals—it does not determine eligibility or prescribe. Export results as a PDF to bring to your first endocrinology or internal medicine appointment. The tool follows ICMR-aligned framing for Indian BMI thresholds and lists questions about waist circumference and prior lifestyle programmes. Results are educational only and never shared with third parties or insurers without your consent. Free to use on kesho.health. ## Quick questions ### Is Who Qualifies for GLP-1 in India information on Kesho medical advice? No. Kesho provides drug-class education only. Always consult a qualified endocrinologist, internal medicine specialist, or cardiologist for personalised treatment decisions. ### Where is the full guide? See our complete medically reviewed guide linked on this page for in-depth coverage with references and India-specific context. ### What is the short answer on who qualifies for glp-1 in india? In India, GLP-1 therapy may be considered for type 2 diabetes when first-line treatment fails, and for obesity at BMI ≥27.5 without comorbidities or ≥25 with comorbidities (prediabetes, hypertension, NAFLD). Final eligibility is determined by your physician after full assessment. ## Complete guide [who-qualifies-glp-1-india](https://www.kesho.health/blog/who-qualifies-glp-1-india) · [MD](https://www.kesho.health/md/blog/who-qualifies-glp-1-india) ## Related guides - [GLP-1 Without Diabetes in India: Who Can Use It for Weight?](https://www.kesho.health/blog/glp-1-without-diabetes-india) - [GLP-1 Explained: A Complete Guide for Indian Patients](https://www.kesho.health/blog/glp-1-explained-india) - [GLP-1 vs Bariatric Surgery in India: Comparing Options](https://www.kesho.health/blog/glp-1-vs-bariatric-surgery-india) --- *Drug-class education only — not medical advice. [Kesho](https://www.kesho.health)*